Iloprost in Acute Respiratory Distress Syndrome (ThIlo)

University Hospital Tuebingen

Status and phase: Completed; Phase 3

Conditions: Respiratory Distress Syndrome, Adult

Treatments: Drug: control; Drug: Iloprost

Study type: Interventional

Funder types: Other

Identifiers

NCT03111212

ThIlo

Details and patient eligibility

About

The patients will be randomized into one of two groups. Both groups will receive standard care as is state of the art. The intervention group will receive Iloprost nebulized as inhalative therapy.

Enrollment: 150 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Horowitz index <300
• Bilateral opacities on frontal chest radiograph
• requirement of positive pressure ventilation
• no clinical evidence of left atrial hypertension
• enrollment within 48h of onset of ARDS
• mechanical ventilation <7 days

Exclusion criteria

• age <18 years
• mechanical ventilation >7 days
• patient, surrogate or physician not committed to full intensive care support
• pregnancy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

150 participants in 2 patient groups, including a placebo group

Iloprost

Active Comparator group

Treatment:

Drug: Iloprost

control

Placebo Comparator group

Treatment:

Drug: control